Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1-Reference-Cited by-同舟云学术

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1

Published:2020-05 Issue:10 Volume:28 Page:115481
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Fensome Andrew,Ambler Catherine M.,Arnold Eric,Banker Mary Ellen,Clark James D.,Dowty Martin E.,Efremov Ivan V.,Flick Andrew,Gerstenberger Brian S.,Gifford Roger S.,Gopalsamy Ariamala,Hegen Martin,Jussif Jason,Limburg David C.,Lin Tsung H.,Pierce Betsy S.,Sharma Raman,Trujillo John I.,Vajdos Felix F.,Vincent Fabien,Wan Zhao-Kui,Xing Li,Yang Xiaojing,Yang Xin

Funder

Pfizer

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference23 articles.

1. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease;O'Sullivan;Mol Immunol,2007

2. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases;Virtanen;BioDrugs: Clin Immunotherapeutics, Biopharmaceut Gene Therapy,2019

3. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases;Clark;J Med Chem,2014

4. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050;Fridman;J Immunol (Baltimore, Md: 1950),2010

5. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms;Quintas-Cardama;Blood,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship;Bioorganic Chemistry;2024-11

2. Recent Catalytic Routes to 3-Azabicyclo[3.1.0]hexane Derivatives;Russian Journal of Organic Chemistry;2024-03

3. Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics;MedComm – Oncology;2024-03

4. Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship;Molecular Diversity;2024-01-18

5. Organotitanium and Organozirconium Reagents;Reference Module in Chemistry, Molecular Sciences and Chemical Engineering;2024